New hope for recurrent brain cancer? drug combo trial launches

NCT ID NCT07297212

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two drugs, pumitamig and bevacizumab, alone or together with temozolomide, in 75 adults whose glioblastoma has returned after standard treatment. The goal is to see if these combinations can shrink tumors and control the disease. Participants will receive intravenous infusions or oral medication, and doctors will monitor for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pumitamig (also called PM8002, BNT327, BMS-986545) and bevacizumab, with temozolomide in one arm
What this could lead to: If successful, this could point toward a new treatment option for people with recurrent glioblastoma, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early phase 2 trial with only 75 participants, so results may not apply to everyone. The drugs may cause side effects, and there is no guarantee they will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Affiliated Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, 250117, China
Affiliated Tumor Hospital of Chongqing Medical University
RECRUITING

Chongqing, 350209, China
Beijing Tiantan Hospital, Capital Medical University
RECRUITING

Beijing, 100070, China
Huashan Hospital, Fudan University
RECRUITING

Shanghai, 201107, China
Shenzhen Second People's Hospital
RECRUITING

Shenzhen, 518000, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.